Primrose Bio Launches Innovative RNA Polymerase for mRNA
Primrose Bio, Inc. introduces its latest innovation, the Prima RNApols ExTend Cap AU, designed to boost the efficiency in manufacturing self-amplifying mRNA vaccines and therapeutics. This next-generation RNA polymerase is engineered specifically to elevate the capping efficiency while reducing the presence of double-stranded RNA during production.
Enhancing Manufacturing of Self-Amplifying mRNA
With the impressive capabilities of ExTend Cap AU, manufacturers can achieve high-quality self-amplifying mRNA with significantly lower requirements for capping reagents, template DNA, and RNA polymerase. This advancement is not only tailored for AU cap analogs but also minimizes unwanted side products known as dsRNA. The outcome is a more cost-effective production process that ultimately enhances product quality.
Key Benefits of ExTend Cap AU
The introduction of Prima RNApols ExTend Cap AU brings several noteworthy benefits that can propel research and development in the field:
- High AU capping efficiency, achieved with minimized cap usage, streamlining the overall reagent needs.
- Ultra-low amounts of dsRNA, lessening the unwanted IVT byproducts that often complicate purification processes.
- Increased yield of self-amplifying RNA (saRNA), which ensures superior integrity and fidelity compared to traditional T7 polymerases.
- Cost-efficient manufacturing that utilizes reduced amounts of templates, enzymes, and cap analogs, leading to significant savings.
Addressing Industry Challenges
CEO Drew Burch emphasized the ongoing challenges faced by developers in the realm of mRNA therapeutics. Despite some products gaining regulatory approval globally, there is a critical need for enhanced tools that can produce long template RNA with better accuracy and cleanliness. The launch of this advanced tool is a step forward in addressing the challenges of reagent costs and downstream purification processes.
Availability and Applications
Currently, the Prima RNApols ExTend Cap AU is available for research applications. Notably, GMP-grade versions of this RNA polymerase, adhering to ISO 13485:2016 certified quality systems, are accessible for both clinical and commercial manufacturing of mRNA products. This availability allows researchers and manufacturers alike to explore more effective solutions in their production workflows.
About Primrose Bio, Inc.
Primrose Bio is dedicated to developing and commercializing innovative technologies that fill gaps in the industry's production systems, ensuring scalable and efficient manufacturing. The company offers a range of advanced products including Prima RNApols, which significantly improve mRNA manufacturing processes. With robust solutions like Pfenex Expression Technology and the PeliCRM197 carrier protein, Primrose has supported numerous leading pharmaceutical firms in achieving remarkable results in their product development.
Frequently Asked Questions
What is Prima RNApols ExTend Cap AU?
Prima RNApols ExTend Cap AU is a novel RNA polymerase introduced by Primrose Bio, aimed at enhancing the efficiency of self-amplifying mRNA production.
How does ExTend Cap AU improve capping efficiency?
ExTend Cap AU improves capping by enabling higher efficiency with reduced reagent needs, allowing for a more streamlined manufacturing process.
What are the benefits of using this RNA polymerase?
This RNA polymerase offers benefits like increased yield, high AU capping efficiency, and reduced amounts of unwanted byproducts, leading to improved mRNA quality.
Is Prima RNApols ExTend Cap AU available for commercial applications?
Yes, GMP-grade versions of Prima RNApols ExTend Cap AU are available for clinical and commercial mRNA manufacturing needs.
What is Primrose Bio’s main focus?
Primrose Bio focuses on creating and commercializing production technologies that enhance manufacturing efficiency and scalability for various therapeutic products.
